Mainz Biomed's collaboration with Thermo Fisher aims to advance mRNA-based colorectal cancer screening technologies. ColoAlert improvements reduce retesting rates, delivering results in 2–3 days ...
Benzinga (Video) on MSN12d
Mainz Biomed $MYNZ & Thermo Fisher Partner On Next-Gen Colorectal Cancer Screening ProductMines Biomed, a molecular genetics diagnostic company, has entered into a collaborative agreement with Thermo Fisher ...
Shareholders who hold their shares in brokerage accounts or in "street name" will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker's particular ...
NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Mainz Biomed (MYNZ) announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback